1. Anti-infection Apoptosis
  2. Bacterial TNF Receptor
  3. Mutanolysin

Mutanolysin is a bacteriolytic agent. Mutanolysin is a muralytic enzyme that can prevent hepatic injury. Mutanolysin can digest the cell wall of S. mutans BHT and shows antibacterial activity. Mutanolysin reduces TNF-α production in isolated Kupffer cells stimulated with peptidoglycan-polysaccharide (PG-APS). Mutanolysin can be used for the researches of infection, inflammation and hepatic injury.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Mutanolysin

Mutanolysin Chemical Structure

CAS No. : 55466-22-3

Size Prix Stock Quantité
1 KU En stock
5 KU En stock
10 KU En stock
50 KU En stock

* Veuillez sélectionner la quantité avant d'ajouter des articles.

This product is a controlled substance and not for sale in your territory.

Avis client

Based on 1 Customer Validation

Other Forms of Mutanolysin:

Top Publications Citing Use of Products
  • Activité biologique

  • Pureté et documentation

  • Références

  • Avis client

Description

Mutanolysin is a bacteriolytic agent. Mutanolysin is a muralytic enzyme that can prevent hepatic injury. Mutanolysin can digest the cell wall of S. mutans BHT and shows antibacterial activity. Mutanolysin reduces TNF-α production in isolated Kupffer cells stimulated with peptidoglycan-polysaccharide (PG-APS). Mutanolysin can be used for the researches of infection, inflammation and hepatic injury[1][2][3].

In Vitro

Mutanolysin (200 μg; 36 h) digests PG-APS to reduce TNFα production by purified Lewis rat Kupffer cells by 75%, from 486 pg/mL to 145 pg/mL[1].
Mutanolysin (20 μg/mL, 90 min) lyses and kills live S. mutans AHT and BHT cells after 90 min of incubation, with 99.999% killing efficacy against S. mutans AHT and 99.0% killing efficacy against S. mutans BHT[2].
Mutanolysin exhibits broad lytic activity against gram-positive oral pathogens including S. mutans, A. viscosus, and L. acidophilus, but is inactive against S. aureus, gram-negative bacteria, and yeast[2].
Mutanolysin lyses S. mutans BHT cells by rupturing cell walls[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mutanolysin (200 μg; i.v.; three times per week; within 24 h of SFBL surgery for 4-8 weeks) prevents small bowel bacterial overgrowth-induced hepatobiliary injury in female Lewis rats[1].
Mutanolysin (0.4 mg; i.v.; single dose) completely prevents the development of chronic erosive arthritis, resolves acute arthritis within 14 days, and eliminates granulomatous lesions in visceral tissues[3].
Mutanolysin (0.4 mg; i.v.; single dose; administered 24 h or 3 days post-PG-APS) reduces acute arthritis severity and completely prevents the development of chronic erosive arthritis[3].
Mutanolysin (0.4 mg; i.v.; single dose; administered 14 days post-PG-APS) significantly reduces the severity of chronic joint disease, with only 33% of treated rats developing recurrent disease[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Lewis rats (female, 100-120 g at time of PG-APS injection, arthritis model via intraperitoneal injection of arthropathic PG-APS)[3]
Dosage: 0.4 mg
Administration: i.v.; single dose
Result: Prevented development of chronic erosive arthritis.
Resolved mild acute arthritis within 14 days.
Eliminated granulomatous lesions in liver, spleen, and mediastinal lymph nodes.
Reduced transient limb edema, which peaked at 2-3 hours and subsided by 9 hours.
Showed normal-appearing joint tissue with intact cartilage, no exudate, and only mild residual focal synovial scarring and lining cell hyperplasia at 41 days post-injection.
Demonstrated no chronic erosive arthritis on radiographic assessment.
Maintained tissue PG-APS levels in hind limbs, spleen, liver, and blood equal to or exceeding PBS-treated controls at days 2, 5, and 36 post-injection.
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

[Mutanolysin]

Specific Activity

≥ 4000 U/mg protein

Unit Definition

One unit is defined as the amount of enzyme that will produce a change in absorbance at 600 nm of 0.01 per minute at pH 6.0 at 37°C in a 1 mL volume using a suspension of Streptococcus faecalis cell wall as substrate

Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Références
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Calculateur de molarité

  • Calculateur de dilution

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Vos produits récemment consultés:

Demande en ligne

Your information is safe with us. * Required Fields.

Nom du produit

 

Requested Quantity *

Nom du demandeur *

 

Civilité

Adresse e-mail *

 

Numéro de téléphone *

Department

 

Nom de l'organisation *

City

État

Country or Region *

     

Remarques

Bulk Inquiry

Inquiry Information

Nom du produit:
Mutanolysin
Cat. No.:
HY-P3023
Quantité:
MCE Japan Authorized Agent: